Medicinal – Page 46

Survey of Massachusetts peer recovery coaches’ attitudes toward the use of psychedelics to treat substance use disorders

mycolabadmin

Researchers surveyed peer recovery coaches in Massachusetts about their views on using psychedelics like psilocybin and ketamine to treat addiction. Most coaches felt comfortable supporting this approach and believed they should receive training, but many worried about potential risks and felt that traditional 12-step programs wouldn’t approve. Coaches with personal experience using psychedelics were more supportive than those who hadn’t tried them.

Exploring Therapeutic Potential of Pleurotus ostreatus and Agaricus bisporus Mushrooms against Hyperlipidemia and Oxidative Stress Using Animal Model

mycolabadmin

Oyster and white button mushrooms may help lower cholesterol and protect against heart disease. In a study using rats with high cholesterol, mushroom extracts reduced harmful cholesterol levels and improved the body’s natural defense against oxidative damage. These common, affordable mushrooms contain beneficial compounds that could be incorporated into diets as a natural way to support heart health and manage cholesterol.

Effect on consumers’ sustainable purchase intention of dietary supplement purine labeling

mycolabadmin

This study examined how labeling the purine content on dietary supplements affects whether consumers continue buying them long-term. Researchers found that clearly showing purine levels encourages people to make sustainable choices, especially those concerned about gout or similar health conditions. The effect works by making health-conscious consumers more aware of potential risks and connecting their purchases to both personal health and environmental values.

CORRECTION: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

mycolabadmin

A major research study examining psilocybin’s effectiveness for treating depression has been corrected due to mathematical and data handling errors. The researchers fixed these issues by recalculating statistics and removing duplicate data from their analysis. While the main conclusions remained similar after correction, the authors emphasize this research is still preliminary and should lead to further study before clinical use.

Research progress of edible mushroom polysaccharide-metal trace element complexes

mycolabadmin

This research reviews how edible mushroom polysaccharides can be combined with essential metals like iron, selenium, and zinc to create health-boosting supplements. These complexes improve how our bodies absorb and use these important minerals, offering benefits like better immune function, antioxidant protection, and potential cancer-fighting properties. Scientists are studying different ways to make these complexes and testing their effectiveness for treating various health conditions.

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

mycolabadmin

This study directly compared two popular psychedelic drugs, LSD and psilocybin (magic mushrooms), in 28 healthy volunteers. Researchers found that these substances produce very similar mental effects when given at equivalent doses, with the main difference being that LSD lasts longer. The study establishes that about 20 milligrams of psilocybin is roughly equivalent to 100 micrograms of LSD. These findings could help guide dosing for future psychiatric treatments using these psychedelics.

Toxicology and Analysis of Psychoactive Tryptamines

mycolabadmin

Tryptamines are a growing class of psychoactive drugs that can cause hallucinations and other dramatic changes in perception. These substances, including compounds like DMT and psilocybin from magic mushrooms, work by affecting serotonin receptors in the brain. While some research explores their potential medical use for treating depression and anxiety, they also carry serious risks including dangerous changes in heart rate, body temperature, and mental state. Scientists have developed new laboratory methods to detect these drugs in blood and urine samples to help doctors diagnose and treat overdoses.

A novel synbiotic formulation prevents calcium oxalate stones by restoring gut microbiota homeostasis

mycolabadmin

This study tested a special probiotic and prebiotic combination to prevent kidney stones caused by too much oxalate in the body. The formula containing three beneficial bacteria strains and a plant-based fiber worked better than any single component alone. The treatment restored healthy gut bacteria, protected the intestinal lining, and reduced the amount of oxalate reaching the kidneys, effectively preventing stone formation in animal models.

Pharmacokinetics of Psilocybin: A Systematic Review

mycolabadmin

This review examines how the body processes psilocybin, a compound from magic mushrooms being studied for treating depression and anxiety. When taken orally, psilocybin is quickly converted to its active form, psilocin, which reaches peak levels in the bloodstream within 1-4 hours and is eliminated mainly through urine. The body’s ability to process psilocybin involves specific liver enzymes that vary between individuals, potentially explaining why people respond differently to the same dose and why certain medications can interfere with its effects.

The Gut Mycobiome for Precision Medicine

mycolabadmin

This comprehensive review explores how fungi in our gut play important roles in our health and disease. While fungi make up only a tiny fraction of our gut microbiota, they have outsized effects on conditions like diabetes, inflammatory bowel disease, and even certain cancers. The review discusses how scientists study these fungi and how understanding individual fungal profiles could lead to personalized medical treatments tailored to each person’s unique microbial makeup.

Research Topic: Medicinal